Mounjaro®
Starting from £179.99/mo
Start journey Learn moreYes. The Mounjaro injection has shown some of the strongest average weight-loss results of any medicine licensed in the UK. In the SURMOUNT-1 trial, adults taking the highest dose lost around 20–21% of their body weight over 72 weeks alongside a reduced-calorie diet and increased activity. That kind of result doesn't happen with every medicine in this class. Mounjaro (tirzepatide) is a prescription-only treatment, so a qualified prescriber has to assess whether it's clinically suitable for you before any treatment begins — your biology, health history and current medicines all factor in. What follows is a clear-eyed look at how the injection works in practice, what the evidence actually shows, and what a typical treatment course looks like in real terms.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Mounjaro contains tirzepatide, a molecule that mimics two gut hormones simultaneously: GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1). Most other weight-loss injections target GLP-1 alone. Both pathways are involved in appetite regulation and the feeling of fullness after eating. When both are activated together, the brain receives a stronger satiety signal, gastric emptying slows, and the urge to eat (especially between meals) becomes noticeably quieter for most people.
That mechanism is why the SURMOUNT-1 trial results stood out. Published in the New England Journal of Medicine, the study found average weight reductions of around 15%, 19.5% and 20.9% at the 5, 10 and 15 mg doses respectively over 72 weeks. The NHS's patient guidance on tirzepatide describes it as a dual GIP and GLP-1 receptor agonist, confirming this is the only licensed weight-loss injection in the UK working across both pathways. Knowing the mechanism helps explain why results vary: if your appetite is more biology-driven than habit-driven, the dual signal tends to land harder.
It's also worth knowing that Mounjaro is a Black Triangle (▼) medicine in the UK, meaning the MHRA monitors it closely for ongoing safety data. That's standard for newer medicines, not a red flag. Our Mounjaro overview covers the regulatory background in more detail.
Each Mounjaro KwikPen contains four weekly doses. You inject subcutaneously (under the skin) once a week, on the same day each week if you can manage it. Your prescriber chooses the starting strength and sets the titration plan. The opening four weeks are almost always at 2.5 mg, a dose whose job is settling your system rather than producing significant weight loss. Nausea and other gastrointestinal effects are most common in the early weeks, and a slow start reduces the chance they become disruptive.
After that, the dose increases roughly every four weeks (5 mg, then 7.5 mg and so on) until you reach either the target maintenance dose or the highest dose you tolerate comfortably. Not everyone reaches 15 mg, and that's fine; meaningful weight reduction happens at lower doses too. The NICE appraisal of tirzepatide (TA1026) notes that if less than 5% of body weight has been lost after six months at the highest tolerated dose, continuing treatment should be reviewed.
The injection itself goes into the abdomen, thigh or upper arm, rotating the site each week. If you're new to self-injection, our guide on where to inject Mounjaro for weight loss walks through the practical details of choosing and rotating your site. The pen is pre-filled and pre-set, so there's no drawing up of doses or measuring involved.
Clinical trial results are averages across thousands of participants. Your own result depends on the dose you reach, how well you manage the diet and activity components, and individual factors your prescriber can discuss with you. That said, the SURMOUNT-1 figures are striking enough to be worth quoting clearly: at 15 mg over 72 weeks, more than a third of participants lost at least 25% of their starting body weight. That's a figure that didn't exist in the licensed weight-loss landscape before tirzepatide.
Head-to-head, the SURMOUNT-5 trial (New England Journal of Medicine, 2025) compared tirzepatide directly against semaglutide 2.4 mg in adults with obesity and found tirzepatide produced greater average weight reduction over 72 weeks. This is the strongest direct comparative evidence available.
Results are also tied to consistency. Missing injections or stopping and restarting without clinical guidance tends to blunt the effect. A question our prescribers hear most weeks is whether the medicine keeps working long-term, the evidence so far suggests it does during active treatment, though weight generally returns if the medicine is stopped without underlying lifestyle changes in place. Details on how Mounjaro is used for weight loss in real-world practice go deeper on this.
The most common side effects are gastrointestinal: nausea, loose stools, constipation, indigestion, burping. They cluster around dose increases and usually settle within a week or two as your body adjusts. Fatigue and mild headache are also reported. Most people find these manageable, particularly because the titration schedule is designed to give your system time to adapt.
Rarer but serious effects require prompt attention. Severe stomach pain (particularly pain that reaches through to the back, with or without vomiting) can be a sign of pancreatitis and needs same-day medical assessment. In January 2026 the MHRA issued a Drug Safety Update specifically flagging acute pancreatitis as a known but infrequent risk with GLP-1 medicines; anyone on Mounjaro should know this symptom pattern. Suspected side effects can be reported via the MHRA Yellow Card scheme.
Mounjaro is not recommended in pregnancy, while breastfeeding, or for people trying to conceive, and it's not licensed for under-18s. If you take an oral contraceptive, a prescriber will likely advise adding a non-oral method of contraception for the first four weeks of treatment and for four weeks after each dose increase, because tirzepatide can reduce pill absorption. The safety picture in full is covered on our page on Mounjaro injection safety.
If you'd like to understand your options across all licensed treatments, our weight-loss treatments page is the starting point, it's also where you can begin a free consultation, reviewed the same day by a named GPhC-registered prescriber. For context on what private treatment typically costs, the Mounjaro weight-loss injections page covers pricing and what's included. One transparent price covers your consultation, prescription, treatment and free next-working-day delivery, no hidden charges added afterwards. That matters when the medicine in your fridge cost a meaningful amount. Worth checking what's actually included before you commit to any provider.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.